Xstelos Holdings Inc.’s (OTCPINK: XTLS) share volume skyrocketed on May 6th, with 2,869,020 shares exchanging hands, over 64 times greater than its three month daily average of 44,170 shares.
With no recent news, one can only speculate why this recent jump in volume occurred. But here is what we do know about the company:
Xstelos Holdings, Inc. operates a specialty pharmaceutical company in the United States. Its principal product includes Testim, a gel for testosterone replacement therapy. The company has licensed its Testim product to Auxilium Pharmaceuticals, Inc, which markets it in the United States, Europe, and Canada. Xstelos Holdings, Inc. owns and leases a 16,434 square foot commercial building situated on approximately 14 acres of land in Exeter, New Hampshire. The company is based in New York, New York.
PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:
AutoloGel Still Focus of Cytomedix Inc.’s Business Plan
Cytomedix Inc.’s (OTCQX: CMXI) share volume surged on May 6th, with 1,409,586 shares exchanging hands, more than four times higher than its three month daily average of 412,530 shares.
This uptick in volume comes after Cytomedix Inc. recently announced it remains focused on its commercial launch initiative for AutoloGel with the goal of driving sales in the estimated $3.4 billion U.S. chronic wound market.
AutoloGel has been cleared by the FDA for use on a variety of exuding wounds and the Company is in the process of launching it, with Medicare coverage and sufficient payment, into the estimated $3.4 billion U.S. chronic wound market. The final payment decision by the Center for Medicare and Medicaid Services (CMS) came into effect on January 1st this year, significantly expanding the coverage for AutoloGel and allowing providers in the outpatient setting to treat a broad patient population with a variety of wounds.
"We will continue to focus our time and resources on the successful development and implementation of our reimbursement and customer support functions of the AutoloGel System for chronic wounds," continued Mr. Rosendale. "We have assembled a talented and experienced commercial team, and continue to work with CMS to expand access to AutoloGel within our Medicare National Coverage Decision."
CMXI closed at $.509 on May 6th, $.056 (9.91%) lower than its previous close of $.565.
OncoSec Medical Inc. Presents New Data
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, saw its share volume continue to sink with 897,871 shares changing hands, significantly lower than its three month average daily volume of 3,436,034 shares.
The company recently announced new data demonstrating that electroporation with DNA-based IL-12 in mice can lead to systemic anti-tumor immune responses in distant untreated lesions.
"Although preliminary, our recent data underscores the importance of researching combination therapies using our ImmunoPulse technology with checkpoint inhibitors and immune activators to optimize their therapeutic effects," said Punit Dhillon, President and CEO of OncoSec. "We now know - at least in regard to the ability of IL-12 to generate systemic anti-tumor immune responses – that it works in a manner consistent with what we have observed in patients. This study is demonstrating for the first time the mechanism by which DNA IL-12 may convert non-responding tumors to responding tumors using our ImmunoPulse technology."
ONCS closed at $.77 on May 6th, down $.025 (3.14%) from its previous close of $.795.
Amarantus Bioscience Holdings Inc.’s (OTCQB: AMBS) share volume remained strong on May 6th, with 4,684,521 shares exchanging hands, slightly lower than its three month average daily volume of 5,878,464 shares.
Amarantus recently announced it has opened an office in Geneva, Swirzerland in preparation for the establishment of a Swiss affiliate.
"As we continue to implement our strategy of building a world class organization, the expansion of the Company into the European market represents an important corporate milestone for the Company," said Gerald E. Commissiong, President & CEO of Amarantus. "Amarantus is operating in a global environment, where our diagnostic and therapeutic product candidates will have impact around the world. Opening an office in Switzerland positions the Company in proximity to great innovation, as evidenced by neuroscience- and life science focused programs and initiatives such as the Human Brain Project (HBP) and Campus Biotech. HBP is part of the Future and Emerging Technologies Flagship Program, a new initiative launched by the European Commission, and it was recently announced that the HBP research will move to the Campus Biotech site in Geneva. The mission of Campus Biotech is to become a center of excellence and focal point for scientists and entrepreneurs in the life science sector. We believe Geneva and surrounding area will become an important center for innovation in the CNS space in the years ahead, and we are excited about our prospects going forward as a transatlantic company."
AMBS closed at $.078 on May 6th, $.005 (6.85%) higher than its previous close of $.073.
Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.
Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.pennypickalerts.com
Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.